Skip to content
DataLookout
Menu

STARS-RC08NCT07935759

Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal Cancer

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathologic complete response (pCR) rate
Timeframe: From baseline up to the time of surgery (approximately 14 weeks after radiotherapy initiation)

Arms and interventions

short course radiotherapy followed by surufatinib and toripalimab in locally advanced rectal cancerExperimental

Radiation: radiotherapy

Drugs: Toripalimab, Surufatinib 250mg/d qd once daily

Sites

1 site in 1 country

  • the first hospital of Jilin UniversityChangchun, Jilin, China